Sinopharm Modern's Subsidiary to Invest Nearly RMB 100 Million in Topical Drug Industry Upgrade; Board Approves Asset Impairment Provision and Governance Revisions

China Interview Network DataSHANGHAI MODERN PHARMACEUTICAL CO LTD held the second meeting of the ninth board of directors on January 26, 2026, during which multiple significant motions were reviewed and approved. Key decisions included: approving the investment of 97.7727 million yuan by the holding subsidiary Three Pharmaceutical Drug Group (Wuhu) Co., Ltd. in constructing the "Topical Medicine Industry Upgrade Project" to enhance its production capacity and quality control standards in dermatological topical medicines and ophthalmic drugs, thereby strengthening market competitiveness. The board also passed a motion regarding the provision for impairment, with further details announced separately. Additionally, to improve corporate governance, the meeting approved revisions to three governance policies: the "Board Nomination Committee Working Procedures," "Board Compensation and Evaluation Committee Working Procedures," and the "Basic Internal Control System." All motions received unanimous approval from the board, aligning with the company's strategic development plan to promote sustainable and high-quality growth.